Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Current Deferred Revenue (2024 - 2025)

Historic Current Deferred Revenue for BioRestorative Therapies (BRTX) over the last 4 years, with Q1 2025 value amounting to $150000.0.

  • BioRestorative Therapies' Current Deferred Revenue changed N/A to $150000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $150000.0, marking a year-over-year change of. This contributed to the annual value of $164349.0 for FY2014, which is N/A changed from last year.
  • BioRestorative Therapies' Current Deferred Revenue amounted to $150000.0 in Q1 2025.
  • In the past 5 years, BioRestorative Therapies' Current Deferred Revenue ranged from a high of $150000.0 in Q1 2025 and a low of $80700.0 during Q2 2024